The literature discussed above provide compelling evidence to suggests the targeting of co-stimulatory pathways such as OX40/OX40L, or other similar molecules in this family, can promote robust expansion of antigen-specific effector T cells in response to safe attenuated VACV vaccine strains and peptide antigen.